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eural stem cells (NSCs) are 
generally deﬁ  ned by their 
dual capacity to self-renew and 
differentiate into more specialized cell 
types such as neurons and glia. NSCs 
have been the object of many studies 
aimed at neuron replacement therapy 
in several degenerative conditions of 
the central nervous system such as 
Parkinson disease, Alzheimer disease, 
multiple sclerosis, and amyotrophic 
lateral sclerosis.
Pathotropism (movement towards 
diseased areas), a yet incompletely 
understood characteristic of NSCs, 
makes them particularly attractive 
candidates not only to replace 
damaged tissue in degenerative 
pathologies, but also to deliver 
therapeutic molecules in patients with 
disseminated metastatic cancer [1]. By 
2000, several studies had shown that 
upon intracranial transplantation into 
animal models of brain cancer, NSCs 
are able to speciﬁ  cally migrate to sites 
of neoplasia [2  –4], possibly in response 
to chemotactic signals emanating 
from cancer cells. Perhaps even more 
surprisingly, this tropism of neural 
stem cells can be exploited to target 
extracranial tumors of both neural and 
non-neural origins [5].
Exploiting Pathotropism to 
Develop Treatments: A New 
PLoS ONE Study
In the launch issue of PLoS ONE, 
Aboody et al. report on the successful 
eradication of whole-body disseminated 
metastases in a mouse model of 
neuroblastoma [6]. The researchers 
took advantage of the tumor-tropic 
(selective migration towards cancer 
cells) properties of neural stem cells 
engineered to express an anti-cancer 
prodrug converting enzyme [6].
The experimental design they used 
is elegant in its straightforwardness 
(Figure 1). The tumor-tropic neural 
cell line HB1.F3.C1, originally derived 
by immortalization of human fetal 
telencephalon primary stem cells with a 
retrovirus encoding the v-myc oncogene 
[7], was employed as an in vivo delivery 
vector. To this aim, HB1.F3.C1 cells 
were engineered to encode for a 
secreted form of rabbit carboxylesterase 
(rCE), an enzyme capable of activating 
the anticancer prodrug CPT-11. Mice 
bearing disseminated neuroblastoma 
metastases were intravenously 
administrated with the modiﬁ  ed NSCs 
and systemically treated with CPT-
11. The in vivo–administered rCE-
secreting stem cells selectively migrate 
to disseminated metastases where the 
enzyme activates the CPT-11 prodrug, 
thus increasing antitumor activity. 
Long-term (>6 months) monitoring 
of the treated animals showed 100% 
tumor-free survival when compared to 
control groups (50% survival).
These promising results point to the 
surprising ability of NSCs to selectively 
migrate to tumor sites independently 
of size and anatomical localization 
of the disseminated neuroblastoma 
metastases. Overall, the study by 
Aboody and collaborators lays a solid 
preclinical basis for experimental trials 
towards the eradication of disseminated 
metastatic disease in patients with 
cancer by intravenous administration 
of (neural) stem cells engineered 
to express therapeutic molecules. 
However, several research and safety 
issues should be considered.
Research and Safety Issues
Ideally, (neural) stem cell lines used 
as in vivo vectors for the delivery of 
therapeutic molecules should retain 
the main features of both stem and 
progenitor cells, namely: (1) the 
capacity to differentiate in vivo in a 
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Figure 1. Schematic Diagram of the Protocol Used by Aboody and Colleagues
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predictable and controlled fashion, and 
(2) a sustained replication potential 
to allow propagation and expansion 
in vitro. The latter is usually achieved 
through immortalization by oncogene 
transformation, a procedure that raises 
obvious concerns about the potential 
tumorigenicity of the delivery vehicle.
From this point of view, the use of 
primary, rather than immortalized, 
stem cells may represent an attractive 
and safer alternative. However, 
in vitro expansion and genetic 
manipulation of primary stem cells 
is often cumbersome and not easily 
achieved, which represents a serious 
limitation for their use in the clinic. 
Alternatively, the identiﬁ  cation of the 
growth factors underlying sustained 
replication potential in immortalized 
cells, and their implementation in 
the culture medium of primary (non-
immortalized) stem cells, is likely to 
enhance their long-term and more 
efﬁ  cient in vitro propagation. Notably, 
in contrast to mesenchymal stem cells, 
the v-myc immortalized HB1.F3.C1 
NSCs do not replicate in vivo and are 
non-tumorigenic [7,8].
A second but equally relevant aspect 
is the stem cells’ capacity to respond to 
disease-speciﬁ  c chemotactic signals. A 
limited number of stem cell attractants 
like VEGF (vascular endothelial 
growth factor), SDF1 (stromal cell-
derived factor 1), and other cytokines 
emanating from brain pathologies 
have already been identiﬁ  ed. However, 
it should be evident that additional 
and possibly disease-speciﬁ  c signals 
should be identiﬁ  ed, together with 
the corresponding receptors on the 
cell surface of the stem cells used as 
therapeutic vehicles.
During the last few years, much effort 
has been devoted to the identiﬁ  cation 
of cell surface markers for the 
prospective isolation of adult stem cells 
from several tissue-speciﬁ  c niches such 
as the mammary gland [9]. Analysis of 
the pathotropism of these primary cells 
or of cell lines derived from them is 
likely to provide additional and disease-
speciﬁ  c stem cell vehicles to test in 
preclinical animal models.
Immunogenicity also represents a 
potential complication of any stem 
cell–based therapeutic application. 
While autologous stem cell sources 
represent the ideal solution, they can 
be a less practical option, especially 
if immortalization and/or further 
genetic manipulation of the vehicle 
cells are necessary. Although treatment 
with immune suppressive drugs may 
bypass the problem, additional studies 
are necessary to evaluate the true 
immunogenic potential of stem cells 
from allogeneic sources.
Conclusion
Apart from the direct application 
for the treatment of metastatic 
diseases, the tropism of stem cells 
is likely to ﬁ  nd applications in a 
broad spectrum of pathologies 
mainly depending on the migratory 
characteristics of the vehicle cells and 
of the chemoattractants emanating 
from the lesions in question. The 
main challenge ahead is to identify 
primary or immortalized stem 
cells from various niches for their 
capacity to migrate and localize at 
sites of focalized disease and deliver 
therapeutic molecules in situ without 
replicating in vivo.  
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